Increasing Prevalence of Autoimmune Disorders is Driving Growth of Tumor Necrosis Factor Inhibitor Drugs Market

Tumor necrosis factor or TNF is a vital protein that plays a major role in stimulating the immune systems of human beings. Several medical researches and studies have shown that the patients who suffer from autoimmune disorders such as rheumatoid arthritis or anklylosing spondylitis have greater levels of tumor necrosis factor.
Precisely because of the prevalence of such diseases, the global tumor necrosis factor inhibitor drug market is on the rise. Increasing usage of therapeutics such as Golimumab, Etanercept, Infliximab, and Certolizumab among others are also helping to drive the growth of the market. In addition to this, the market is projected to have a fiercely competitive landscape, which is expected help in the growth of the global market in coming years.

Get Sample Copy of this Report @

Some of the notable developments in the global tumor necrosis factor inhibitor drugs market are listed below:

• On June 25, 2019, Allergen Inc. was acquired by AbbVie Inc. Both the companies signed on a definitive transaction agreement which allowed AbbVie to takeover Allergen in stock as well as cash transaction. The idea behind the takeover was to boost the revenue by merging the profile and scale up the profitability. AbbVie Inc. planned to use Allergen’s network to expand its market reach.
• In June 2019, Janssen Pharmaceutical Company announced the best results from the phase III Discover 1 & 2 studies. These studies evaluated the safety and efficiency of guselkumab and compared it with results of placebo in adult patients suffering from psoriatic arthritis.
• On June 29, 2019, Amgen Inc., and Institute for Protein Design (University of Washington) announced a collaboration that will help covering in numerous projects with an aim of testing new and upcoming technologies. The collaboration will also try to develop new protein-building approaches that can be used for the manufacturing of new medicines.

Read Comprehensive Overview of Report @

Some of the other key players in the global tumor necrosis factor inhibitor drugs market include names such as Samsung Bioepis, Takeda Pharmaceutical Company, Pfizer Inc., and Merck & Co. among others.